Mehmet Veli Karaaltın, M.D.

 

 

 

 

 

 

 

(Image: Mehmet Veli Karaaltın, M.D.)

MIAMI, Jan. 18, 2018—Global Stem Cells Group CEO Benito Novas has named Mehmet Veli Karaaltın, M.D., Associate Professor of Plastic, Aesthetic, and Reconstructive Surgery, (European Board Certified), and hand surgery, head, and maxillofacial surgery specialist to the GSCG Advisory Board Faculty.

Karaaltın practices in Istanbul, Turkey.

Born in Iraq-Kirkuk in 1972, Karaaltın moved to the United States with his family, living in West Lafayette, Indiana and Los Angeles until 1988, when he moved to Istanbul.

After graduating from Istanbul University’s Cerrahpaşa English Medical Faculty, Karaaltın received a national examination from Hacettepe University in Ankara, Turkey, where he was 12th out of 25000 doctoral candidates.  In 2012, he passed and completed all ID exams required by the European Society of Plastic Surgery. He ​​is a member of the European Council of Plastic Reconstructive and Aesthetic Surgery and the International Society of Aesthetic Plastic Surgery (ISAPS).

In addition to his work in aesthetic applications, Karaaltın is also known for his work in microvascular free flaps, nerve transfers, facial surgery, and tissue transplants.

Karaaltın also practices cellular therapy and tissue regeneration for healing diabetic wounds, severe burns, and Buerger’s disease. He is one of only a few physicians in the world who offer surgical treatment for Lymphedema-Elephant Disease with microvascular lymph node transfer. In addition, Karaaltın uses

3-D technology to perform aesthetic rhinoplasty.

“It is a pleasure to welcome Dr. Karaaltın to the Global Stem Cells Group Advisory Board,” says GSCG  CEO Benito Novas. “He brings a wealth of knowledge in aesthetic regenerative medicine to the table, and we look forward to a long and productive alliance.”

To learn more, visit the Global Stem Cells Group website, email inf@stemcellsgroup.com, or call +1 305 560 5337.

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global stem cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world.

 

Mehmet Veli Karaaltın, M.D.

stem cell training

 

 

 

 

 

 

 

ISSCA President Daeyong Kim, Ph.D., and Vice President Benito Novas to hold next ISSCA chapter meeting in Seoul, Korea Jan. 24-26, 2018.

MIAMI, Jan. 18, 2018— ISSCA President Daeyong Kim, Ph.D. has announced the next chapter meeting will be held Jan. 24 – 26, 2018 in Seoul, Korea.

The meeting will be held by Kim and ISSCA Vice President Benito Novas and will address all ISSCA chapter directors and board members.

ISSCA Chapter directors from the U.S., Costa Rica, Argentina, Spain, and Morocco will be in attendance. During the three-day event, chapter directors will receive training in the latest regenerative medicine clinical application protocols as well as applications for manipulating and harvesting stem cells in lab conditions.

ISSCA will also establish strategies for 2018, focusing on promoting excellence and setting standards in the field of publication, research, related education, and certification in regenerative medicine during the event.

The organization intends to set the entire 2018 agenda for regenerative medicine training for 2018 during the meeting, including:
• The Hands on Training Agenda
• The  Cell Therapy and Engineering Tissue Fellowship

To learn more about ISSCA, visit the stemcellglobal.org website, email info@stemcellsgroup.com, or call +1305 560 5337.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.  Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

 

ISSCA chapter meeting

Junaid A. Syed, M.D.

 

 

 

 

 

 

 

(Image: Junaid A. Syed, M.D.)

ISSCA President Daeyong Kim, Ph.D., has named Junaid Sayed, M.D. president of ISSCA’s U.S. chapter.

MIAMI, Jan. 18, 2018—International Society for Stem Cell Application (ISSCA) President Daeyong Kim, Ph.D., has named Junaid Sayed, M.D. president of ISSCA’s U.S. chapter. Sayed is Board Certified physician with extensive training in aesthetic medicine.

As president of the U.S. chapter, Sayed will represent and promote ISSCA activities the USA, including ISSCA’s Stem Cell Certification Training and Stem Cell Conference events. He will also share the latest information on regenerative medicine clinical applications with the U.S, medical community.

“We are happy to have Dr. Sayed represent ISSCA in the U.S., and as a collaborator in our efforts to introduce new clinical applications to the medical community,” says Kim. “He brings a wealth of experience and expertise to the ISSCA organization.”

To learn more about ISSCA, visit the stemcellglobal.org website, email info@stemcellsgroup.com, or call +1305 560 5337.

About ISSCA:

ISSCA 2018 training agenda

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.  Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

 

 

 

 

 

 

 

 

 

 

 

MIAMI, Jan. 15, 2018—Global Stem Cells Group (GSCG) subsidiary Stem Cell Center Network, the world’s largest collective support and advisory network of regenerative medicine clinics and physicians, has announced the opening a new facility in San Jose, Puerto Rico in January 2018.

Stem Cell Center Puerto Rico will provide stem cell treatments for a variety of conditions, including osteoarthritis, erectile dysfunction, and urinary incontinence.  Adimarket, also a subsidiary of GSCG, will provide Stem Cell Center Puerto Rico with state-of-the-art products and technology, such as the Integrated Stem Cell Workstation

Global Stem Cells Group CEO Benito Novas named Juan Colon, M.D. to head Stem Cell Center Puerto Rico as medical director. Colon is a urologist who has spent the past year working to help prostate cancer patients. He earned his medical degree from Recinto de Ciencias Médicas in San Juan and trained in the latest regenerative medicine protocols in December 2017 at Stem Cell Center San Jose, Costa Rica.

The Stem Cell Center Network has aggressively launched and rapidly expanded new fellowship programs, events, and other regenerative medicine events over the past five years and currently has members practicing in 25 countries.

The new San Juan center will treat patients with a variety of degenerative conditions with emphasis on osteoarthritis, according to Novas.  

For more information, visit the Stem Cell Center Network website, the Global Stem Cells Group website, email info@stemcellsgroup.com, or call +1305 560 5337.

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global stem cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world.

About Stem Cell Center Network:

Stem Cell Center Network, a division of Global Stem Cells Group, is an international network of medical practitioners dedicated to bringing stem cell therapies to patients worldwide.
Network physicians are experts in their fields and believe that stem cell treatments are to the future of medicine. Each Network physician is dedicated to providing the best treatments and contributing to the global store of regenerative medicine knowledge and research.

About Adimarket:

Adimarket, Inc.,
a division of the Global Stem Cells Group, is a one-stop, cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and healthcare professionals.

Adimarket was founded to provide practitioners the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting-edge treatments.

ISSCA 2018 training agenda

 

 

 

 

 

 


ISSCA will conduct the next regenerative medicine certification training course in Mexico City, Feb. 9-10, 2018. The two-day course focuses on harvesting adipose and bone marrow stem cells from patients in a clinical environment.

MIAMI, Jan. 15, 2018—The International Society for Stem Cell Application (ISSCA) announced plans to hold its next regenerative medicine certification training course in Mexico City, Feb. 9 – 10, 2018.

The two-day, hands-on training course will focus on harvesting adipose and bone marrow stem cells from patients in a clinical environment. Qualified physicians learn skills that can be used to treat patients in their practices, and for career advancement. The course provides participating physicians with training in stem cell applications to treat a variety of conditions.

Participating physicians will also receive access to the online stem cell training course to review all content and procedures introduced in the 2-day clinical training course, patient forms and guidelines, procedure informed consent forms, didactic lectures, training booklets, and more.

ISSCA’s stem cell certification course offers hands-on, personalized training in harvesting stem cells from a live patient. ISSCA has trained more than 2,000 physicians worldwide. The course is only available to eight physicians per training, so it is important to sign up early to reserve a seat.

The ISSCA regenerative medicine training course was developed for physicians and high-level practitioners to learn techniques in harvesting and reintegrating stem cells.

Stem cell therapies continue to revolutionize the healthcare industry and help improve the quality of life for patients.

To learn more about the ISSCA certification training course and register to participate, visit the Stem Cell Training Course website, email info@stemcellsgroup.com, or call 305-560-5337.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.  Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

 

 

 

 

ISSCA 2018 training agenda

 

 

 

 

 

 


ISSCA has announced plans to launch the first bilingual (English and Spanish) regenerative medicine newsletter.
 

MIAMI, Jan. 15,  2018—The International Society for Stem Cell Application (ISSCA) will launch the first bilingual (English and Spanish) regenerative medicine newsletter January 23, 2018. The monthly newsletter will be available for free to email subscribers and shared through ISSCA social media channels.

The newsletter will include three sections:

  1. Regenerative Medicine Business News
  2. Regenerative Medicine Research and clinical applications
  3. Upcoming Regenerative Medicine Training

Regenerative Medicine Business News will provide the latest updates on policies, legislative, regulatory and reimbursement initiatives to support research and development of regenerative medicine products, and business development and investor information on opportunities in the fast-growing stem cell and regenerative medicine market.

Regenerative Medicine Research and clinical applications will follow the latest findings on regenerative medicine research and development—from tissue engineering to cell therapies, and the different challenges involved in live tissue handling and manufacturing. In addition, the newsletter will include information on the latest clinical applications of regenerative medicine therapies.

The newsletter will also include schedules and registration information on upcoming regenerative medicine training and certification courses, along with registration information.

To subscribe to ISSCA’s newsletter, send an email request with your contact information to info@stemcellsgroup.com.

To learn more, visit the ISSCA website, email info@stemcellsgroup.com, or call 305-560-5337.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.  Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

ISSCA has announced its sponsorship of XXVI Jornadas Mediteraneas – Mediterranean Days of Therapeutic Confrontations in Medicine and Cosmetic Surgery to be held in Barcelona, Spain May 11 – 13, 2018. ISSCA has committed to sponsoring the event for five consecutive years.

MIAMI, Jan. 15, 2018—The International Society for Stem Cell Application (ISSCA) has announced its sponsorship of XXVI Jornadas Mediteraneas -Mediterranean Days of Therapeutic Confrontations in Medicine and Cosmetic Surgery in Barcelona, Spain May 11 – 13, 2018. ISSCA has committed to sponsoring Jornadas Mediteraneas for five consecutive years.

Global Stem Cells Group CEO and medical marketing expert Benito Novas will launch his new book, “Digital Marketing in Your Aesthetic Clinic” in Europe during the event. He will also speak about the latest digital marketing strategies critical to physicians looking to grow their practices.

Additionally, Alfredo Hoyos,M.D., world-renowned plastic surgeon and  Global Stem Cell Group’s chief scientific officer (CSO) will speak about utilizing stem cells to obtain better results in aesthetic surgery procedures.

The event, one of the most influential European medical conferences, will focus on topics such as regenerative medicine and stem cell therapies, skin aging, body rejuvenation and remodeling, and 21st Century tools for professional practices to capture and retain new patients. ISSCA will host two master regenerative medicine certification training classes during the conference. The conference will be held at Hotel Meliá Sitges in Barcelona.  –more—     To learn more about XXVI Jornadas Mediteraneas and register to attend, visit the Stem Cell Conference website, email mailto:info@stemcellsgroup.com, or call 305-560-5337.

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

About ISSCA:
ISSCA 2018 training agenda

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.  Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global Stem Cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world.

###

 

ISSCA Barcelona Symposium

 

 

 

 

 

Image: Benito Novas

 

Global Stem Cells Group founder and CEO Benito Novas was recognized as a leader in regenerative medicine at the XVIII International Congress of Aesthetic Medicine, Aesthetic Surgery and Obesity, Dec. 2, 2017, in Mexico City.

MIAMI, Dec. 22, 2017—Benito Novas, founder and CEO of Global Stem Cells Group (GSCG), earned recognition for his leadership in regenerative medicine at the XVIII International Congress of Aesthetic Medicine, Aesthetic Surgery and Obesity, Dec. 2, 2017, in Mexico City.

Novas accepted the recognition, signed and presented to him by Congress President Rector Doctor Arturo Conde at the event, honoring him for helping thousands of physicians around the world bring regenerative medicine therapies to their clinical practices.

Novas provided training and equipment to physicians throughout South America, North America, Europe, Asia, and the Middle East through GSCG affiliate companies Stem Cell Training, Adimarket online regenerative medicine store, and Stem Cell Center Network (present in more than 30 cities globally).

Novas is a global entrepreneur, manager, and keynote speaker with expertise in the field of specialized marketing focused on biotechnology, life sciences, and healthcare development.

The philosophy that has driven him to launch and grow his companies is the desire for a perpetual flow of knowledge and innovation with regard to the role of stem cells in modern medicine.

“My aim is to accelerate the process of getting promising stem cell research and technology developed into treatments and therapies, and to make them readily available to benefit the health and well-being of a broad range of patients,” he says.

Using specialized marketing techniques focused on stem cells and their impact on the field of aesthetic surgery, Novas created a multi-company corporation based on his visionary approach to healthcare management and regenerative medicine.

To learn more about Global Stem Cells Group, visit the company website, email info@stemcellsgroup.com, or call 305-560-5337.

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global Stem Cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world.

Benito Novas recognized

 

 

 

 

 

 

 

Adimarket, a subsidiary of Global Stem Cells Group, has announced an agreement with biotechnology company Alolotl Biologix to distribute biological products for regenerative medicine applications worldwide.

 MIAMI, Dec.21, 2017— Adimarket, a subsidiary of Global Stem Cells Group (GSCG), and its subsidiary has announced an agreement with Phoenix, Arizona-based Alolotl Biologix to distribute the biotechnology company’s products for regenerative medicine applications worldwide.

Alolotl Biologix focuses on research to optimize the use of human biologicals and to develop biological-related products to foster regeneration and healing for a range of conditions, including orthopedic impairments, wound care, pain management, ophthalmic, cardiovascular, cosmetic, and more.

Adimarket will make the following amniotic liquid products available to qualified practitioners through its online store www.adimarket.net:

AxoBioFluid® C Amniotic Allograft Cryopreserved Liquid, cryopreserved liquid allograft derived from the amniotic membrane that provides structural tissue to advance soft tissue repair, replacement, and reconstruction. Product details:

  • Human allograft under FDA regulation 21 CFR Part 1271 and section 361 of the PHS
  • Immune privileged with anti-inflammatory and anti-bacterial properties
  • A rich source of growth factors, proteins, cytokines, hyaluronic acid, and collagen scaffolds
  • Contains extracellular matrix components for cellular   attachment and proliferation
  • Cryopreserved for an extended shelf life

AxoBioFluid® physician benefits

  • Procedures are efficient and do not require special instrumentation.
    •  The use of AxoBioFluid® is billed as patient pays, which makes it a great alternative revenue source.
    •  A library of research papers to demonstrate efficacy degenerated tissue is provided.

AxoBioFluid® patient benefits

Relevant Conditions

AxoBioFluidâ C Amniotic Allograft Cryopreserved Liquid, cryopreserved liquid allograft derived from the amniotic membrane that provides structural tissue to advance soft tissue repair, replacement, and reconstruction. Product details:

  • Human allograft under FDA regulation 21 CFR Part 1271 and section 361 of the PHS
  • Immune privileged with anti-inflammatory and anti-bacterial properties
  • A rich source of growth factors, proteins, cytokines, hyaluronic acid, and collagen scaffolds
  • Contains extracellular matrix components for cellular   attachment and proliferation
  • Cryopreserved for an extended shelf life

AxoBioFluidâ physician benefits

  • Procedures are efficient and do not require special instrumentation.
    •  The use of AxoBioFluid® is billed as patient pays, which makes it a great alternative revenue source.
    •  A  library of research papers to demonstrate efficacy is provided.

AxoBioFluid® Amniotic Allograft Cryopreserved Liquid is a cryopreserved liquid allograft derived from the placental components of the amnion to advance soft tissue repair, replacement, and reconstruction. It is classified as minimally manipulated under FDA regulation 21 CFR Part 1271 and section 361 of the PHS. Benefits of AxoBioFluid® AxoBioFluid® is a human allograft fluid derived from the amniotic layer of the placenta. The two primary cell lines which reside in the amnion are human mesenchymal stromal cells (hMSC) and human amnion epithelial cells (hAEC). Both of these cells are considered to be pluripotent stem cells. AxoBioFluid® contains growth factors released while amniotic cells are grown in culture such as epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and transforming growth factor – beta (TGF-β). These proteins are essential for fetal growth and development and express significant therapeutic benefits when used as a treatment for various injuries and degenerative conditions. AxoBioFluid® is immuneprivileged, anti-inflammatory, anti-fibrotic, pro-vascular, and cytoprotective because of the cells being sourced from the amnion. These secreted factors also signal endogenous progenitor cells to promote regeneration and repair of damaged or degenerated tissue.

AxoBioFluid

  • Degenerative disorders such as osteoarthritis
    • Joint pain
    • Inflammatory conditions such as:
  • Bursitis
  • Tendonitis
  • Fasciitis
  • Epicondylitis
  • Soft tissue injuries such as:
  • Ligament & Tendon sprains
  • Muscle & Meniscus tears
  • Wound Care

AxoBioMembrane, a dehydrated allograft membrane patch derived from the amnion that advances wound repair, skin replacement, and reconstruction. Product details:

  • Human allograft under FDA regulation 21 CFR Part 1271 and section 361 of the PHS
  • Immune privileged with anti-inflammatory and anti-bacterial properties
  • Contains extracellular matrix components for cellular attachment and proliferation
  • Dehydrated and terminally e-beam sterilized for an extended shelf life.

AxoBioMembraneä Amniotic Allograft Membrane, like all allograft tissue products, has been subjected to recovery microbiological study and has been terminally sterilized with electron beam sterilization.  It works by forming fibrin-elastin bonds at the wound site, ensuring excellent wound adherence. This generates a barrier that protects exposed nerve endings from irritants, providing pain relief while creating a favorable environment for tissue repair and regeneration. In addition, the AxoBioMembrane™ prevents excessive moisture loss by creating a vapor barrier at the wound surface. Growth factors present in the membrane are released into the wound bed, promoting angiogenesis leading to new blood supply needed for cellular migration, proliferation and ultimately, wound repair. Infection is one of the biggest concerns with chronic wounds. AxoBioMembrane™ functions as a bacteriostatic agent, which can inhibit the growth of bacteria at the wound site and reduce the rate infection. It has also been reported to have anti-fibrotic properties, which can reduce scarring. The membrane contains glycoprtoteins found exclusively in the amnion. AxoBioMembrane™ lacks specific surface antigens, which make it immune-privileged and anti-inflammatory.

AxoBioMembraneä physician benefits

  • Procedures are efficient and do not require special instrumentation.
  • AxoBioMembrane™ is billed as patient pays, which makes it a great alternative revenue source.
  • We provide a library of research and white papers to demonstrate efficacy.

AxoBioMembraneä  patient benefits:

  • Pain Reduction
  • Wound Adherence
  • Less Scarring
  • Faster Healing
  • Neovascularization
  • Wound Barrier
  • Anti-bacterial
  • Immune Privileged

AxoBio products are available to purchase on the Adimarket Website.

For more information, visit the Adimarket regenerative medicine online store website, email info@stemcellsgroup.com, or call 305-560-5337.

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global stem cell’s mission is to be the largest recognized stem cell and regenerative medicine network in the world. 


About Adimarket:

Adimarket, Inc.,
a division of the Global Stem Cells Group, is a one-stop, cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals.

Adimarket was founded to provide practitioners the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting-edge treatments.

About Alolotl Biologix:
amniotic biofluid
Axolotl Biologix, Inc. is an innovative biotechnology leader in regenerative medicine through research, technology and clinical application. Axolotl Biologix is expanding the human body’s ability to regenerate by developing and manufacturing regenerative human cell and tissue, medical technologies that are disrupting traditional, more invasive, painful, and expensive treatment protocols. For more information, visit www.axobio.com.

###

 

amniotic biofluid

Escazú, Costa Rica

 

 

 

 

Image: CIMA Hospital in Escazú

 

 

Global Stem Cells Group announces plans to expand its Stem Cell Center Network to include a new stem cell treatment center in Escazú, Costa Rica.

MIAMI, Dec. 21, 2017—Global Stem Cells Group (GSCG), a world leader in stem cell and regenerative medicine, has announced the opening of a new stem cell center in its Stem Cell Center Network in Escazú, Costa Rica. The new center will focus on treating patients who suffer from regenerative illnesses.

The new center, located at the CIMA Hospital in Escazú, will be headed by Leslie Mesen, M.D., a specialist in anti-aging medicine.

The new center is part of Global Stem Cells Group’s worldwide expansion of its clinical presence, partnering with qualified physicians experienced in stem cell therapies to open new clinics and utilize GSCG stem cell products and protocols inpatient treatments. GSCG has established similar alliances in 33 cities worldwide.

The new center’s location at the CIMA Hospital in Escazú offers a safe and luxurious venue for patients traveling from the U.S. and other countries for treatment.

Mesen studied medicine at the Ibero-American University (UNIBE) in San José, Costa Rica. He leads numerous regenerative medicine courses in the United States and throughout Latin America. He is board certified in anti-aging and regenerative medicine by The American Academy of Anti-Aging Medicine.

Mesen has served as chief medical officer of three highly-recognized anti-aging institutes, including the Costagenics Age Management program (2007-2010), Anti-Aging Institute of the Americas (2010-2013) and the Anti-Aging and Wellness Clinic (2014-present).

The new center in Escazú is equipped with the latest, cutting-edge regenerative medicine technology. Mesen was trained in Global Stem Cells Group facilities in the U.S.

“This new center, headed by Dr. Mesen, is a perfect reflection of Global Stem Cells Group’s commitment to meet the growing needs of clients and patients,” says GSCG founder and CEO Benito Novas. “Together with Dr. Mesen, we will continue to provide the latest medical technology and benefits available through our regenerative medicine products and protocols.

Global Stem Cells Group hopes to approve five more franchises in early 2108. If you are a pysician interested in learning more about joining the world’s largest regenerative medicine practitioner network please contact us www.stemcellcenter.net

GSCG provides stem cell treatments for a variety of conditions, diseases, and aesthetic treatments at facilities worldwide. The new facility will have an international staff experienced in administering the leading cellular therapies available.

Global Stem Cells Group’s Escazú clinic is certified for the medical tourism market, and staff physicians are board-certified or board-eligible. GSCG clinics provide services in more than 10 specialties, attracting patients from the United States and around the world.

GSCG is committed to providing the highest standards of services and technology, expert and compassionate care, and a philosophy of exceeding the expectations of their international patients.

To learn more about Global Stem Cells Group, visit the GSCG website,  email info@stemcellsgroup.com, or call +1305 560 533

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global Stem Cell Group’s aim is to be the largest recognized stem cell and regenerative medicine network in the world.

 

 

Escazú, Costa Rica.